健康大视野·医学分册2023,Issue(3) :66-68.

幽门螺旋杆菌阳性十二指肠溃疡患者应用不同三联疗法进行治疗的效果及差异性分析

陈姗 刘恒梅
健康大视野·医学分册2023,Issue(3) :66-68.

幽门螺旋杆菌阳性十二指肠溃疡患者应用不同三联疗法进行治疗的效果及差异性分析

陈姗 1刘恒梅1
扫码查看

作者信息

  • 1. 枣庄市台儿庄区人民医院内一科,山东 枣庄 277400
  • 折叠

摘要

目的:探讨不同三联疗法用于治疗幽门螺旋杆菌(Hp)阳性十二指肠溃疡(DU)患者的疗效差异.方法:按随机数表法对120例、2021年8月~2022年8月期间收治的Hp阳性DU患者展开分组,各60例/组.均行克拉霉素、阿莫西林治疗,基于此,对照组、观察组分别加用奥美拉唑、雷贝拉唑治疗,对比两组疗效.结果:同比对照组,治疗后观察组的总有效率及Hp根除率较高,溃疡愈合及Hp根除时间较短,不良反应率及CRP、IL-6、TNF-α水平较低(P< 0.05).结论:雷贝拉唑三联疗法用于治疗Hp阳性DU患者临床疗效及安全

Abstract

Objective To investigate the difference of therapeutic effects of different triple therapies on duodenal ulcer (DU) patients with Helicobacter pylori (Hp) positive.Methods: 120 patients with Hp positive DU admitted from August 2021 to August 2022 were randomly divided into 60 groups.All patients were treated with clarithromycin and amoxicillin.Based on this, the control group and the observation group were treated with omeprazole and rabeprazole respectively to compare the efficacy of the two groups.Results: Compared with the control group, the total effective rate and Hp eradication rate of the observation group after treatment were higher, the ulcer healing and Hp eradication time were shorter, the adverse reaction rate and CRP, IL-6, TNF- α The level was lower (P<0.05).Conclusion: Rabeprazole triple therapy is effective and safe in the treatment of Hp positive DU patients.

关键词

幽门螺旋杆菌阳性/十二指肠溃疡/三联疗法/治疗效果

Key words

Helicobacter pylori positive/Duodenal ulcer/Triple therapy/treatment effect

引用本文复制引用

出版年

2023
健康大视野·医学分册
中国保健协会

健康大视野·医学分册

ISSN:1005-0019
参考文献量13
段落导航相关论文